MTARGIO
DEAD

Serial Number

88408985

Owner

Mirati Therapeutics, Inc.

Attorney

Eric R. Moran

Filing Date

Apr 30, 2019

Add to watchlist:

No watchlists yet
View on USPTO

MTARGIO Trademark

Serial Number: 88408985

MTARGIO is a trademark filed by Mirati Therapeutics, Inc. on April 30, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Mirati Therapeutics, Inc. (34 trademarks)

San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

April 30, 2019

Registration Date

Not Registered

Goods & Services

research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals

pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of bladder cancer; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of renal cancer; pharmaceutical preparations for the treatment of renal cell carcinoma; pharmaceuticals comprising small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of bladder cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of renal cancer; pharmaceuticals comprising small molecules for the treatment of renal cell carcinoma; pharmaceuticals comprising compounds; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors

Filing History

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 4, 2020 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 4, 2020 COAR
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 27, 2020 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 27, 2020 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 15, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jul 15, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jul 15, 2019 CNRT
ASSIGNED TO EXAMINER
Jul 12, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 16, 2019 NWOS
NEW APPLICATION ENTERED
May 3, 2019 NWAP